Abstract
The mechanisms associated with aldosterone production both systemically and locally as well as the effects of aldosterone blockade on the pathophysiology of heart failure (HF) have been extensively reviewed in this series and elsewhere. This article will review the clinical evidence supporting the use of aldosterone blocking agents (AB)in patients with HF and speculate on some potential future uses.
MeSH terms
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
-
Diuretics / pharmacology*
-
Eplerenone
-
Heart Failure / drug therapy*
-
Heart Failure / physiopathology
-
Humans
-
Mineralocorticoid Receptor Antagonists / pharmacology*
-
Randomized Controlled Trials as Topic
-
Spironolactone / analogs & derivatives*
-
Spironolactone / pharmacology*
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Diuretics
-
Mineralocorticoid Receptor Antagonists
-
Spironolactone
-
Eplerenone